Synthetic surfactants: Where are we? Evidence from randomized, controlled clinical trials

Journal of Perinatology

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Moya, F ^a,b  

^a NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; LUCINACTANT; OXYGEN; PHOSPHATIDYLGLYCEROL; PLACEBO; PORACTANT; PUMACTANT; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C;

AGE DISTRIBUTION; ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; CHILDHOOD MORTALITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL REFLUX; HUMAN; LUNG DYSPLASIA; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOTHORAX; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; SEPSIS; SYSTEMATIC REVIEW;

ANIMALS; BIOLOGICAL PRODUCTS; BRONCHOPULMONARY DYSPLASIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; FATTY ALCOHOLS; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; INTENSIVE CARE, NEONATAL; PHOSPHATIDYLGLYCEROLS; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; POLYETHYLENE GLYCOLS; PROTEINS; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65549131196     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2009.26     Document Type: Conference Paper

References (27)

1. Ainsworth SB, Milligan DW. Surfactant therapy for respiratory distress syndrome in premature neonates: A comparative review. Am J Respir Med 2002; 1: 417-433.
2. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001; (2) Art. No.: CD000144.
3. Curstedt T, Jörnvall H, Robertson B, Bergman T, Berggren P. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: Characterization and biophysical activity. Eur J Biochem 1987; 168: 255-262.
4. Notter RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 2002; 114: 21-34.
5. Clark JC, Wert SE, Bachurski CJ, Stahlman MT, Stripp BR, Weaver TE et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA 1995; 92: 7794-7798.
6. Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, deMello DE et al A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93: 1860-1863.
7. Nogee LM, Dunbar III AE, Wert SE, Askin F, Hamvas A, Whitsett JA. Brief report: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573-579.
8. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991; 254: 566-568.
9. Moya F, Maturana A. Animal-derived surfactants versus past and present synthetic surfactants: Current status. Clin Perinatol 2007; 34 145-177.
10. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993; 123: 757-766.
11. Sehgal SS, Ewing CK, Richards T, Taeusch HW. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study. J Natl Med Assoc 1994; 86: 46-52.
12. Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996; 97: 1-6.
13. Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV. Comparative efficacy of Exosurf and Survanta on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol 1997; 17: 455-460.
14. da Costa DE, Pai MGK, Al Kusaiby SM. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: Experiences in a developing country. Pediatr Pulmonol 1999; 27: 312-317.
15. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A et al., for the International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018-1029.
16. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings J, Jung AL et al A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997; 100 39-50.
17. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996; 128: 396-406.
18. Kukkonen AK, Virtanen M, Järvenpää A-L, Pokela ML, Ikonen S, Fellman V. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 2000; 89: 556-561.
19. Ainsworth SB, Beresford MW, Milligan DWA, Shaw N, Matthews J, Fenton A et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25 to 29 weeks' gestation: A randomised trial. Lancet 2000; 355: 1387-1392.
20. Andersson S, Kheiter A, Merritt TA. Oxidative inactivation of surfactants. Lung 1999; 177: 179-189.
21. Revak SD, Merritt TA, Cochrane CG, Heldt GP, Alberts MS, Anderson DW et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996; 39: 715-724.
22. Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404-410.
23. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J et al., for the Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very preterm infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030-1038.
24. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C et al. SELECT and STAR Study Investigators. One-year follow up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: Results from 2 multicenter, randomized, controlled trials. Pediatrics 2007; 119: E1361-e1370.
25. Kattwinkel J. Synthetic surfactants: The search goes on. Pediatrics 2005; 115: 1075-1076.
26. Halliday HH. Surfactants: Past, present and future. J Perinatol 2008; 28: S47-S56.
27. Engle WA, the Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121: 419-432.